Kenneth S. Hu, MD | NYU Langone Health

Dr. Kenneth S. Hu

Claim this profile

New York University School of Medicine

Studies Neck Cancer
Studies Head and Neck Cancers
6 reported clinical trials
16 drugs studied

Affiliated Hospitals

Image of trial facility.
New York University School Of Medicine
Image of trial facility.
Laura And Isaac Perlmutter Cancer Center At NYU Langone

Clinical Trials Kenneth S. Hu is currently running

Image of trial facility.

ePVA Monitoring System

for Head and Neck Cancer

The PI and the research team developed the New York University (NYU) Electronic Patient Visit Assessment (ePVA) for head and neck cancer (HNC) as a patient-reported outcome measure (PRO) for the early detection of uncontrolled symptoms. The ePVA is digital patient-reported symptom monitoring system, providing actionable information at point-of-care that enables clinicians to provide real-time interventions. The study aims to advance the science of cancer care delivery by testing the effectiveness of the ePVA as a digital patient-reported monitoring system for patients with HNC in real-world settings and identify implementation strategies that optimize the effectiveness of the ePVA in diverse rural and urban settings. The study hypothesis is that participants assigned to the ePVA arm will have better swallowing, taste and smell, and social function than participants assigned to usual care arm at 4 weeks after completing radiation therapy.
Recruiting1 award N/A3 criteria
Image of trial facility.

Chemotherapy + Radiation Therapy

for Head and Neck Cancer

This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer the begins in the thin, flat cells (squamous cell). Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cetuximab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The purpose of this study is to compare the usual treatment (radiation therapy with cisplatin chemotherapy) to using radiation therapy with docetaxel and cetuximab chemotherapy, and using the usual treatment plus an immunotherapy drug, atezolizumab.
Recruiting1 award Phase 2 & 321 criteria

More about Kenneth S. Hu

Clinical Trial Related1 year of experience running clinical trials · Led 6 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Kenneth S. Hu has experience with
  • Cisplatin
  • Intensity-Modulated Radiation Therapy
  • Cisplatinum
  • Dose-Deescalated Treatment
  • Standard Radiation Treatment
  • Photobiomodulation (PBM) Therapy

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Kenneth S. Hu specialize in?
Is Kenneth S. Hu currently recruiting for clinical trials?
Are there any treatments that Kenneth S. Hu has studied deeply?
What is the best way to schedule an appointment with Kenneth S. Hu?
What is the office address of Kenneth S. Hu?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security